Hyper-CVAD: a regimen for all seasons.
Matthew D Seftel
https://pubmed.ncbi.nlm.nih.gov/32589970/Actively Recruiting
Led by Alliance for Clinical Trials in Oncology · Updated on 2026-11-03
303
Participants Needed
460
Research Sites
21 weeks
Total Duration
Researchers are evaluating the side effects and effectiveness of adding inotuzumab ozogamicin to frontline chemotherapy for young adults aged 18 to 39 with newly diagnosed B acute lymphoblastic leukemia, a type of blood cancer. Inotuzumab ozogamicin is a targeted therapy that delivers a chemotherapy drug directly to cancer cells. This phase III trial aims to confirm the safety and improve event-free survival compared to standard pediatric-inspired chemotherapy. Participants receive a combination of chemotherapy drugs in several treatment courses, including remission induction, remission consolidation, interim maintenance, delayed intensification, and maintenance therapy. Those in the experimental group receive inotuzumab ozogamicin intravenously on specific days alongside chemotherapy, with additional treatments like blinatumomab given if minimal residual disease is detected. Procedures such as bone marrow biopsies and imaging are performed throughout. Participants will be closely monitored through blood tests, bone marrow samples, imaging scans, and symptom assessments. Researchers will measure outcomes like event-free survival, disease-free survival, overall survival, response rates, and adverse events over several years. After treatment, participants are followed regularly for up to 10 years to assess long-term effects and survival.
CONDITIONS
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
D
Daniel J. DeAngelo, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Alliance for Clinical Trials in Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Chemotherapy plus Inotuzumab Ozogamicin | Frontline Chemotherapy Alone | Hyper‑CVAD Regimen (Current Standard of Care) |
|---|---|---|---|
| What the regimen is | Frontline chemotherapy regimen combined with inotuzumab ozogamicin as the experimental arm in the randomized trial | The standard multiagent frontline chemotherapy regimen used as the control arm in the randomized trial | Hyper‑CVAD is a widely used frontline chemotherapy backbone in adult B‑ALL |
| Role in trial | Investigational arm combining chemotherapy with inotuzumab ozogamicin | Control arm with frontline chemotherapy alone | Not part of the trial but represents current common practice in similar patients |
| Primary use | To evaluate whether adding inotuzumab ozogamicin improves outcomes when added to frontline chemotherapy | To serve as the comparator chemotherapy backbone for evaluating additive benefit | Current standard induction chemotherapy regimen in adult B‑ALL management |
| How it is given or performed | Multiagent chemotherapy plus intravenous inotuzumab ozogamicin added to standard scheme | Multiagent frontline chemotherapy alone as described in trial protocol | Alternating cycles of intensive chemotherapy (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone and high‑dose methotrexate with cytarabine) often with CNS prophylaxis |
| Evidence status | Efficacy outcomes are being studied; results pending | Known chemotherapy backbone with established historic outcomes | Hyper‑CVAD regimen established with long‑term survival data and widely used in adult B‑ALL |
| Important limitations | Outcomes not yet established and additional toxicity from inotuzumab ozogamicin possible | Historic outcomes may not reflect improvements with newer targeted or immunologic agents | Standard chemotherapy has known toxicities and may be less effective in CD22‑positive disease without targeted agents |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 29 days
Participants receive remission induction therapy with chemotherapy drugs and intrathecal treatments. Bone marrow biopsies and other tests are performed to assess response.
Multiple visits including drug infusions and assessments
Duration - Up to 3 years
Participants who respond to induction are randomized to receive either standard chemotherapy alone or chemotherapy with inotuzumab ozogamicin, followed by consolidation, maintenance, and additional therapies as needed.
Regular visits for drug administration, bone marrow biopsies, and imaging
Duration - Up to 10 years
After treatment completion, participants are followed regularly to monitor health and disease status.
Visits every 2 to 6 months depending on time since treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Matthew D Seftel
https://pubmed.ncbi.nlm.nih.gov/32589970/Kara L Davis, Catherine C Yao, Jessica A O Zimmerman...
https://pubmed.ncbi.nlm.nih.gov/41671463/Alliance for Clinical Trials in Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor